Harbour Capital Advisors LLC Decreases Position in Amgen Inc. (AMGN)
Harbour Capital Advisors LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,179 shares of the medical research company’s stock after selling 125 shares during the period. Harbour Capital Advisors LLC’s holdings in Amgen were worth $358,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in AMGN. Swiss National Bank raised its holdings in shares of Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Amgen by 37.4% during the 1st quarter. AQR Capital Management LLC now owns 1,443,129 shares of the medical research company’s stock valued at $236,775,000 after buying an additional 392,538 shares in the last quarter. Morningstar Investment Services LLC raised its holdings in shares of Amgen by 283.8% during the 1st quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock valued at $81,625,000 after buying an additional 367,894 shares in the last quarter. Karp Capital Management Corp purchased a new position in shares of Amgen during the 1st quarter valued at about $54,888,000. Finally, State of Tennessee Treasury Department raised its holdings in shares of Amgen by 51.4% during the 1st quarter. State of Tennessee Treasury Department now owns 783,570 shares of the medical research company’s stock valued at $128,560,000 after buying an additional 265,931 shares in the last quarter. 78.14% of the stock is currently owned by institutional investors.
A number of equities analysts have commented on AMGN shares. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $203.00 price target on shares of Amgen in a research note on Thursday, September 7th. Cann reaffirmed a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Mizuho reaffirmed a “buy” rating and issued a $183.00 price target (down from $195.00) on shares of Amgen in a research note on Monday, August 21st. BidaskClub cut Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Argus lifted their price target on Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $186.04.
Amgen Inc. (NASDAQ AMGN) traded up 0.82% during mid-day trading on Tuesday, reaching $188.01. The company’s stock had a trading volume of 1,344,825 shares. Amgen Inc. has a one year low of $133.64 and a one year high of $188.85. The stock has a 50-day moving average price of $173.58 and a 200-day moving average price of $168.69. The company has a market capitalization of $137.19 billion, a price-to-earnings ratio of 17.12 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $2.84 EPS. Equities research analysts forecast that Amgen Inc. will post $12.57 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were paid a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.47%. Amgen’s payout ratio is currently 41.93%.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/12/harbour-capital-advisors-llc-decreases-position-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.